Literature DB >> 2456917

Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.

S Ueno1, T F Manganaro, P K Donahoe.   

Abstract

Mullerian inhibiting substance (MIS), a glycoprotein responsible for the regression of Mullerian duct in the male mammalian embryo, was recently localized not only in the fetal and newborn testis, but also in the older ovary throughout reproductive life. Bovine MIS purified from newborn testicular tissue inhibited spontaneous oocyte meiosis in vitro in the rat. These studies show that partially purified recombinant MIS produced from a human MIS genomic construct caused inhibition of oocyte meiosis, but when purified to homogeneity, the effect was lost. Addition of low concentrations of the detergent Nonidet P-40, used to maintain stability in the purified bovine preparations, however, restored the MIS inhibitory effect to the human preparation, which could, in turn, be blocked by a polyclonal antibody raised to human recombinant MIS; Nonidet P-40 itself caused no inhibition. Since we have shown that epidermal growth factor (EGF) and MIS are antagonistic in a number of other systems, we tested the effect of EGF on the ability of MIS to inhibit oocyte meiosis. EGF added to the medium at a dose that caused no effect on oocytes (25 ng/ml) blocked the MIS inhibitory action on spontaneous rat oocyte meiosis, while EGF had no effect on a known oocyte meiosis inhibitor, 3-isobutyl-1-methylxanthine. These data indicate that human recombinant MIS can inhibit oocyte meiosis in the ovary and that its regulatory effect can be modulated by EGF, which appears to be an antagonist of MIS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456917     DOI: 10.1210/endo-123-3-1652

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents.

Authors:  A M Trbovich; P M Sluss; V M Laurich; F H O'Neill; D T MacLaughlin; P K Donahoe; J Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 3.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 4.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

5.  Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.

Authors:  Daniel A Dumesic; Timothy G Lesnick; Jacques P Stassart; G David Ball; Ashley Wong; David H Abbott
Journal:  Fertil Steril       Date:  2009-07       Impact factor: 7.329

6.  Variants of the anti-Müllerian hormone gene in a compound heterozygote with the persistent Müllerian duct syndrome and his family.

Authors:  D Carré-Eusèbe; S Imbeaud; M Harbison; M I New; N Josso; J Y Picard
Journal:  Hum Genet       Date:  1992-12       Impact factor: 4.132

Review 7.  The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility.

Authors:  Jure Bedenk; Eda Vrtačnik-Bokal; Irma Virant-Klun
Journal:  J Assist Reprod Genet       Date:  2019-11-21       Impact factor: 3.412

Review 8.  Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors.

Authors:  Jang Heub Kim; David T MacLaughlin; Patricia K Donahoe
Journal:  Obstet Gynecol Sci       Date:  2014-09-17

9.  Regulatory effect of apoptosis on morphological changes in cell mass of porcine blastocyst through supplementation of rapamycin during in vitro culture.

Authors:  Dae Seung Kim; Sang Hwan Kim; Jong Taek Yoon
Journal:  J Adv Vet Anim Res       Date:  2020-10-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.